Astatine-211 (At-211) is one of a handful of promising alpha emitting radioisotopes for cancer therapy. Its short 7.2-hour half-life means that it must be handled quickly to minimize losses due to ...
Researchers in Japan are developing world-leading expertise in making and using the alpha particle emitter, astatine-211 (211 At), which has potential for use as a strong radionuclide therapy for ...
France’s Framatome and IBA (Ion Beam Applications, Euronext), a specialist in particle accelerator technology and ...
Louvain-La-Neuve, Belgium, and Paris, France, 7 February 2025 - Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA ...
Louvain-La-Neuve, Belgium, and Paris, France, 7 February 2025 - Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback